Evaluation of immunoglobulin levels and infection rate in patients with common variable immunodeficiency after immunoglobulin replacement therapy.

نویسندگان

  • Mahin Salehzadeh
  • Asghar Aghamohammadi
  • Nima Rezaei
چکیده

BACKGROUND/PURPOSE Common variable immunodeficiency (CVID) is characterized by decreased serum levels of IgG and increased susceptibility to recurrent infections. The aim of this study was to evaluate the IgG subclass levels of CVID patients. METHODS Twenty-four CVID patients who had been under regular intravenous immunoglobulin replacement therapy for 96.13 +/- 54.83 months were enrolled in this study. Serum IgG and IgG subclass levels, and clinical outcomes for these patients were evaluated after this period of treatment. RESULTS Mean serum IgG levels were significantly increased from 272.91 +/- 185.58 mg/dL at the time of diagnosis to 455.29 +/- 200.23 mg/dL after treatment, while there was no significant difference in the serum levels of IgM and IgA. Decreased serum levels of IgG1 were detected in 75% of the patients studied. Decreased serum levels of IgG2, IgG3 and IgG4 were also detected in 6, 11, and 11 patients, respectively. All patients experienced recurrent infectious diseases either before, or after, diagnosis. CONCLUSION Although serum IgG levels in the patients significantly increased after regular intravenous immunoglobulin replacement therapy, serum IgM and IgA levels remained diminished over time. Furthermore, a number of cases had low levels of IgG subclasses, in spite of normal total IgG levels, which could explain why some patients had continued infections, even after immunoglobulin replacement therapy.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies

    Background: Economic evaluation of subcutaneous immunoglobulin therapy (SCIG) is important, and it has recently been used for treatment of patients with primary immunodeficiency (PID) diseases, and can improve allocation of resources in health care systems. The present research aimed at providing an economic assessment of SCIG and IVIG (intravenous immunoglobulin therapy) adm...

متن کامل

The Significance of B-cell Subsets in Patients with Unclassified Hypogammaglobulinemia and Association with Intravenous Immunoglobulin Replacement Requirement

Background: Patients with unclassified hypogammaglobulinemia (UCH) constitute a diagnostic and therapeutic dilemma, because information concerning the clinical and immunological characteristics of these patients is insufficient. Objective: To evaluate B-cell subsets in cases with UCH and common variable immunodeficiency (CVID) and their association with treatment requirement in UCH patients. Me...

متن کامل

عوارض ناشی از تزریق ایمونوگلوبولین وریدی در بیماران با نقص ایمنی اولیه

Background and Purpose: Intravenous immunoglobulin is used for primary immunodeficiency disorders. There have been some reports that intravenous immunoglobulin causes side effects. The aim of this study was to investigate intravenous immunoglobulin side effects in immunodeficiency patients. Materials and Methods: The study utilized the data of 29 primary immunodeficiency patients that were...

متن کامل

Adverse reactions associated with intravenous immunoglobulin therapy in patients with dermatologic diseases: An 11-year retrospective study

Background: Intravenous immunoglobulin (IVIG) is used to treat many autoimmune and immunodeficiency disorders. The main indications of IVIG in dermatology include treatment for resistant autoimmune bullous diseases, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Although generally welltolerated, various adverse effects can occur.Methods: We designed a retrospective study ...

متن کامل

A Case of Bruton’s Disease with Normal Immunoglobulin G Level

X-linked agamaglobulinemia (XLA) or Bruton’s disease is a genetic disease resulting from a mutation in the Bruton’s tyrosine kinase (Btk) gene. This mutation leads to B cell arrest during differentiation (1). This disease was first described by Ogden Bruton in 1952 (2). Approximately 85% of the affected subjects are male (3). This disorder is inherited as an X-linked recessive trait. Carrier fe...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi

دوره 43 1  شماره 

صفحات  -

تاریخ انتشار 2010